"Treatment"

Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.

There are many ways to treat prostate cancer and radiation therapy is a common treatment for prostate cancer, but many prostate cancer patients want to know what the side effects of radiation therapy are.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

There are many treatment options for bladder cancer, but surgery is a frequently used treatment, and some bladder cancer patients want to know about post-operative diet

If you are suffering from itchy hair and hair loss, it is important to understand the causes of itchy hair and hair loss so that you can get to the root of the problem. For example, some people only have mild hair loss, which can be relieved after certain adjustments, while others have both itchy symptoms and hair loss symptoms that are more pronounced, so it is also important to pay attention to the right treatment

H-Drugs in the leading international journal again!

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.